Research Triangle Park, N.C.-based G1 Therapeutics Inc. is looking to raise money via the sale of 3 million shares of the company.
The news follows the biopharmaceutical company's earlier announcement about its medicine trilaciclib, which improved the immune system of patients undergoing chemotherapy for a type of lung cancer.
J.P. Morgan Securities LLC and Cowen and Co. LLC are the joint book-running managers for the offer. The underwriters have an option to buy an additional 450,000 shares.
